ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc. (NASDAQ:IBRX) announced the early findings of the first five recurrent glioblastoma patients that were treated with its investigational immune-boosting regimen, including ANKTIVA, in this pilot study.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

The company reported that all five patients attained 100% disease control with the regimen that “combines ANKTIVA, an IL-15 agonist being studied for its ability to enhance natural killer (NK) cell activity, NK cell therapy (PD-L1 t-haNK), and Optune Gio Tumor Treating Fields.”

The study showed that the ANKTIVA treatment raised absolute lymphocyte count (ALC) in all five patients who had experienced lymphopenia after standard of care radiation and chemotherapy.

Management stated that the results were highly encouraging, with “5 out of 5 (100%) disease control in 2nd line recurrent glioblastoma receiving a chemotherapy-free immunotherapy with Optune immune-stimulating device.”

Based on these initial findings, ImmunityBio, Inc. (NASDAQ:IBRX) is starting a “randomized trial targeting second-line GBM patients who have recurring disease following standard of care.”

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

While we acknowledge the potential of IBRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IBRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.